GAP ANALYSIS OF PCV IMPACT EVALUATIONS IN SETTINGS OF ROUTINE USE
Scope of Analysis
This report summarizes the use of pneumococcal conjugate vaccine (PCV) and impact evidence as of November 2016 in countries routinely using PCV10 or PCV13. The amount of impact evidence (as opposed to the results) that is published or being collected id described and key gaps are identified, contextualized by current and anticipated country PCV introductions.
Current PCV Use
As of November 2016, 139 countries have introduced PCV in their routine immunization program; 52% (72) of which have an impact evaluation, including at least one country in every WHO region.
This report was produced using VIEW-hub.